Volume : 12, Issue : 04, April – 2025
Title:
COMPARATIVE ANALYSIS OF BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN THE LONG-TERM MANAGEMENT OF PSORIATIC ARTHRITIS
Authors :
Dr. Fatima Qamar, Muhammad Awais Latif, Muhammad Mudassar Shoaib, Muhammad Fahad Khaliq, Yousma Ikram, Muhammad Faizan Zafar
Abstract :
Background: Psoriatic arthritis (PsA) is a composite, chronic erythrogenic disease which is associated with psoriasis, it affects up to 31% of patients with specifically skin disorder. The treatment topography has evolved with significant change in the development of biologic or bDMARDs and targeted synthetic DMARDs or tsDMARDs.
Aim: This study aims to supply a comprehensive and prolonged comparison of bDMARDs and tsDMARDs in the relation of long-term management of PsA, which specifically focusing on their mechanisms of action, efficaciousness, safety, attachment, and long-term outcomes.
Methods: A research-based modified analysis was conducted by using clinical data for trial, overall long-term studies, and evidence of real-world helps to evaluate the performance of both drug classes.
Results: Both bDMARDs and tsDMARDs demonstrate its vigorous efficacy across multiple PsA estate, with distinctive profiles in terms of administration, safety and patient’s preferences. Two main inhibitors play vital role in this research. TNF inhibitors and IL-17/IL-23 inhibitors remain the backbone of biological therapy, while JAK inhibitors and PDE4 inhibitors offer oral alternatives with competitive behavior and effectiveness.
Conclusion: Treatment should be personalized based on the severity of disease, phenotypic, some co existing conditions and preferences of patients. Continued research and signified medicine strategies play a key role tin optimization of long-term PsA and its outcomes.
Keywords: TNF, cytokines, analysis, long term management, keystone.
Cite This Article:
Please cite this article in press Muhammad Fahad Khaliq et al., Comparative Analysis Of Biologic And Targeted Synthetic Dmards In The Long-Term Management Of Psoriatic Arthritis.,, Indo Am. J. P. Sci, 2025; 12(04).
Number of Downloads : 10
References:
1. Montezuma, T., Probst, L. F., & Almeida, M. O. (2024). Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis. Advances in Rheumatology, 64(1), 21.
2. Gao, S., & Song, H. (2025). Efficacy of Biological or Targeted Synthetic Disease‐Modifying Anti‐Rheumatic Drugs in Active Psoriatic Arthritis: A Network Meta‐Analysis of Randomized Controlled Trials. Journal of Clinical Pharmacy and Therapeutics, 2025(1), 6541156.
3. Freites-Nuñez, D., Leon, L., Toledano, E., Candelas, G., Martinez, C., Rodriguez-Laguna, M., … & Abasolo, L. (2024). Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study. Therapeutic Advances in Musculoskeletal Disease, 16, 1759720X241273083.
4. Abedalweli, R., Nguyen, M., & Deodhar, A. (2024). Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review. Expert Review of Clinical Immunology, 20(7), 735-743.
5. Nishimura, N., Onishi, A., Yamamoto, W., Nagai, K., Shiba, H., Okita, Y., … & Morinobu, A. (2024). Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis. Rheumatology, keae603.
6. Künzler, T., Bamert, M., & Sprott, H. (2024). Factors predicting treatment response to biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis–a systematic review and meta-analysis. Clinical Rheumatology, 1-24.
7. Rosenberg, V., Amital, H., Chodick, G., Faccin, F., & Gendelman, O. (2024). Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis. Drugs & Aging, 41(8), 685-697.
8. Ali, R., Lau, A., & Brent, L. H. (2024). The Use of Biologic and Targeted Synthetic Disease-Modifying Drugs in the Treatment of Psoriatic Arthritis. Biologics, 5(1), 1.
9. Novella-Navarro, M., Ruiz-Esquide, V., López-Juanes, N., Chacur, C. A., Monjo-Henry, I., Nuño, L., … & Balsa, A. (2024). Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis. Clinical Rheumatology, 43(9), 2817-2823.
10. Mease, P. J., Reddy, S., Ross, S., Lisse, J. R., Reis, P., Griffing, K., … & Furst, D. E. (2024). Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. Rmd Open, 10(1), e003423.
11. Mease, P. J., Warren, R. B., Nash, P., Grouin, J. M., Lyris, N., Willems, D., … & McInnes, I. B. (2024). Comparative effectiveness of bimekizumab and secukinumab in patients with psoriatic arthritis at 52 weeks using a matching-adjusted indirect comparison. Rheumatology and Therapy, 11(3), 817-828.
12. McDermott, G. C., DiIorio, M., Kawano, Y., Jeffway, M., MacVicar, M., Dahal, K., … & Liao, K. P. (2024, June). Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis. In Seminars in Arthritis and Rheumatism (Vol. 66, p. 152421). WB Saunders.
13. Clemente, D., Leon, L., Nieto-Gonzalez, J. C., Boteanu, A. L., Folguera, L. T., García-Fernández, A. A., … & Abasolo, L. (2025). Incidence and reasons for biologic and targeted synthetic DMARD switching in juvenile idiopathic arthritis: a real-life stratified analysis. Pediatric Rheumatology, 23, 42.
14. Ciurea, A., Goetschi, A., Moeller, B., Nissen, M. J., Buerki, K., Braem, R., … & Micheroli, R. (2024). POS0259 DOES BIOLOGIC DMARD RETENTION IN AXIAL PSORIATIC ARTHRITIS DEPEND ON THE MODE OF ACTION? COMPARISON OF TNF, IL-17, AND IL-23 INHIBITORS IN A LARGE OBSERVATION COHORT. Annals of the Rheumatic Diseases, 83, 373-374.
15. Mease, P. J., Warren, R. B., Nash, P., Grouin, J. M., Lyris, N., Taieb, V., … & McInnes, I. B. (2024). Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison. Rheumatology and therapy, 11(5), 1413-1423.
16. Lin, J., & Ren, Y. (2024). Different biologics for biological-naïve patients with psoriatic arthritis: a systematic review and network meta-analysis. Frontiers in Pharmacology, 15, 1279525.
17. Molina-Collada, J., Alonso, F., Otero, L., Bohórquez, C., Torné, C. D., García, C. P., … & Castrejón, I. (2024, February). Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: results from the BIOBADASER register. In Seminars in Arthritis and Rheumatism (Vol. 64, p. 152341). WB Saunders.